Replies to post #18747 on Synaptogenix Inc (SNPX)

[InTheTrenches]

RE: synthetic analog. Seems like it would depend on what they determine is the optimal preclinical dosing for MS. If a daily dose is required, IV delivery won't work, and getting the synthetic into pill form would make the most sense.

I've heard some development biotechs are being advised to hold news until after the new year...even good trial news has been rewarded with lower share price the past several weeks. Sure hope we hear something by JP Morgan conference (Jan. 10-13).

[VividC]

There was an interesting conflict of interest statement below the abstract. Perhaps trivial but a sign that folks believe in what Bruostatin can do.:
Conflict of interest statement Johns Hopkins University has filed a patent on the application of bryostatin-1 and its derivatives for multiple sclerosis and other disorders, and P.M.K. and M.D.K. are co-inventors on this patent.